NKT cell stimulation with α-galactosylceramide results in a block of Th17 differentiation after intranasal immunization in mice.

Zygmunt, Beata M; Weissmann, Sebastian F; Guzman, Carlos A

dc.contributor.author	Zygmunt, Beata M
dc.contributor.author	Weissmann, Sebastian F
dc.contributor.author	Guzman, Carlos A
dc.date.accessioned	2012-06-19T11:40:47Z
dc.date.available	2012-06-19T11:40:47Z
dc.date.issued	2012
dc.identifier.citation	NKT cell stimulation with α-galactosylceramide results in a block of Th17 differentiation after intranasal immunization in mice. 2012, 7 (1):e30382 PLoS ONE	en_GB
dc.identifier.issn	1932-6203
dc.identifier.pmid	22291945
dc.identifier.doi	10.1371/journal.pone.0030382
dc.identifier.uri	http://hdl.handle.net/10033/229635
dc.description.abstract	In a previous study we demonstrated that intranasal (i.n.) vaccination promotes a Th17 biased immune response. Here, we show that co-administration of a pegylated derivative of α-galactosylceramide (αGCPEG) with an antigen, even in the presence of Th17-polarizing compounds, results in a strong blocking of Th17 differentiation. Additional studies demonstrated that this phenomenon is specifically dependent on soluble factors, like IL-4 and IFNγ, which are produced by NKT cells. Even NK1.1 negative NKT cells, which by themselves produce IL-17A, are able to block Th17 differentiation. It follows that the use of αGCPEG as adjuvant would enable to tailor Th17 responses, according to the specific clinical needs. This knowledge expands our understanding of the role played by NKT cells in overall control of the cytokine microenvironment, as well as in the overall shaping of adaptive immune responses.
dc.language.iso	en	en
dc.rights	Archived with thanks to PloS one	en_GB
dc.subject.mesh	Administration, Intranasal	en_GB
dc.subject.mesh	Animals	en_GB
dc.subject.mesh	Cell Differentiation	en_GB
dc.subject.mesh	Cell Separation	en_GB
dc.subject.mesh	Cells, Cultured	en_GB
dc.subject.mesh	Down-Regulation	en_GB
dc.subject.mesh	Galactosylceramides	en_GB
dc.subject.mesh	Immunization	en_GB
dc.subject.mesh	Lymphocyte Activation	en_GB
dc.subject.mesh	Mice	en_GB
dc.subject.mesh	Mice, Inbred C57BL	en_GB
dc.subject.mesh	Mice, Knockout	en_GB
dc.subject.mesh	Natural Killer T-Cells	en_GB
dc.subject.mesh	Th17 Cells	en_GB
dc.title	NKT cell stimulation with α-galactosylceramide results in a block of Th17 differentiation after intranasal immunization in mice.	en
dc.type	Article	en
dc.contributor.department	Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany. beata.zygmunt@bbsrc.ac.uk	en_GB
dc.identifier.journal	PloS one	en_GB
refterms.dateFOA	2018-06-13T00:29:25Z
html.description.abstract	In a previous study we demonstrated that intranasal (i.n.) vaccination promotes a Th17 biased immune response. Here, we show that co-administration of a pegylated derivative of α-galactosylceramide (αGCPEG) with an antigen, even in the presence of Th17-polarizing compounds, results in a strong blocking of Th17 differentiation. Additional studies demonstrated that this phenomenon is specifically dependent on soluble factors, like IL-4 and IFNγ, which are produced by NKT cells. Even NK1.1 negative NKT cells, which by themselves produce IL-17A, are able to block Th17 differentiation. It follows that the use of αGCPEG as adjuvant would enable to tailor Th17 responses, according to the specific clinical needs. This knowledge expands our understanding of the role played by NKT cells in overall control of the cytokine microenvironment, as well as in the overall shaping of adaptive immune responses.